Yingchao Zhang

Yingchao Zhang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
TXTing Xue
Ting Xue
CXCaina Xu
Caina Xu
YWYu Wang
Yu Wang
YWYanbing Wang
Yanbing Wang
HTHuayu Tian
Huayu Tian
YZYingchao Zhang
Yingchao Zhang
Doxorubicin (DOX) as a traditional chemotherapy drug is restricted in clinical applications due to its poor therapeutic activity and severe side effects. Herein, we prepared a metal–organic framework (MOF) MIL-100 by a microwave-assisted synthesis and DOX was loaded in MIL-100 and then, hyaluronic acid (HA) was modified on the surface of MIL-100 to give DMH NPs. The DMH NPs possessed the following advantages: (1) MIL-100 could serve as a drug carrier with a high DOX loading efficiency; MIL-100 could also generate a hydroxyl radical (˙OH) in the presence of H2O2 for chemodynamic therapy (CDT) via a Fenton-like reaction. (2) To improve the dispersibility of MIL-100, HA was modified on the surface of MIL-100, which could endow MIL-100 with a targeting ability towards tumor tissues. (3) DMH NPs could enhance antitumor efficacy and reduce drug-related toxicity though the combination of chemotherapy and chemodynamic therapy. DMH NPs have enormous potential as a candidate for reducing the systemic toxicity and improving the treatment effect for breast cancer.

13 September 2022 in Materials & Design
Verified
Journal Article
Open access
ZHZhiming Hu
Zhiming Hu
CXCaina Xu
Caina Xu
YLYonghao Liang
Yonghao Liang
TLTaiyuan Liu
Taiyuan Liu
HTHuayu Tian
Huayu Tian
YZYingchao Zhang
Yingchao Zhang

30 May 2024 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Open access
RWRuoyi Wang
Ruoyi Wang
XHXu Huang
Xu Huang
XCXiaoxi Chen
Xiaoxi Chen
YZYingchao Zhang
Yingchao Zhang
Triple-negative breast cancer (TNBC) is an aggressive subtype with the worst prognosis and highest recurrence rates. The treatment choices are limited due to the scarcity of endocrine and HER2 targets, except for chemotherapy. However, the side effects of chemotherapy restrict its long-term usage. Immunotherapy shows potential as a promising therapeutic strategy, such as inducing immunogenic cell death, immune checkpoint therapy, and immune adjuvant therapy. Nanotechnology offers unique advantages in the field of immunotherapy, such as improved delivery and targeted release of immunotherapeutic agents and enhanced bioavailability of immunomodulators. As well as the potential for combination therapy synergistically enhanced by nanocarriers. Nanoparticles-based combined application of multiple immunotherapies is designed to take the tactics of enhancing immunogenicity and reversing immunosuppression. Moreover, the increasing abundance of biomedical materials holds more promise for the development of this field. This review summarizes the advances in the field of nanoparticle-mediated immunotherapy in terms of both immune strategies for treatment and the development of biomaterials and presents challenges and hopes for the future.

18 December 2024 in Cell Adhesion & Migration
Verified
Journal Article
Open access
ZWZeyu Wang
Zeyu Wang
TLTaiyuan Liu
Taiyuan Liu
KHKang He
Kang He
LWLongyun Wang
Longyun Wang
XMXiaoxuan Ma
Xiaoxuan Ma
LZLijing Zhao
Lijing Zhao
Research on the function of HGH1 in breast cancer remains lacking. TCGAand GEO (GSE45827) datasets investigated discrepancies in HGH1 expression in BC. An aggregate of 106 clinical samples were gathered through immunohistochemistry, KM curves were drawn for prognostic analysis, and the function of HGH1 of BC was predicted. Finally, the effects of HGH1 knockdown on MDA-MB-231 and MCF-7 BC cells were verified via CCK8, invasion, wound healing and colony formation assays. HGH1 is highly expressed in BC and is linked to unfavorable prognosis. HGH1 overexpression is connected to keratinization and the cell cycle and is closely related to ER and PR expression and tumor stage in BC patients. Knocking down HGH1 in BC cells inhibited the viability, invasion and migration. Knockdown of HGH1 in breast cancer cell lines can inhibit the viability, invasion and migration of tumor cells.

1 March 2023 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
TLTaiyuan Liu
Taiyuan Liu
YLYonghao Liang
Yonghao Liang
SLSunil Kumar Lalwani
Sunil Kumar Lalwani
YZYingchao Zhang
Yingchao Zhang
Case Report Paget disease of the breast with underlying invasive ductal cancer in neurofibromatosis type 1: a case report Taiyuan Liu, Yonghao Liang, Sunil Kumar Lalwani, Yingchao Zhang

15 July 2025 in Science China Materials
Verified
Journal Article
Closed access
PDF file
ZGZiwen Gao
Ziwen Gao
PZPeng Zhang
Peng Zhang
RYRenyong Yin
Renyong Yin
JWJunqi Wang
Junqi Wang
ZGZhihui Guo
Zhihui Guo
XCXuesi Chen
Xuesi Chen